163 related articles for article (PubMed ID: 16451103)
1. Development of the PANVAC-VF vaccine for pancreatic cancer.
Petrulio CA; Kaufman HL
Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
[TBL] [Abstract][Full Text] [Related]
2. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
4. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
6. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
10. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.
Kaufman HL; Kim-Schulze S; Manson K; DeRaffele G; Mitcham J; Seo KS; Kim DW; Marshall J
J Transl Med; 2007 Nov; 5():60. PubMed ID: 18039393
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.
DiPaola RS; Plante M; Kaufman H; Petrylak DP; Israeli R; Lattime E; Manson K; Schuetz T
J Transl Med; 2006 Jan; 4():1. PubMed ID: 16390546
[TBL] [Abstract][Full Text] [Related]
13. TRICOM: enhanced vaccines as anticancer therapy.
Levy B; Panicalli D; Marshall J
Expert Rev Vaccines; 2004 Aug; 3(4):397-402. PubMed ID: 15270644
[TBL] [Abstract][Full Text] [Related]
14. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
Madan RA; Arlen PM; Gulley JL
Expert Opin Biol Ther; 2007 Apr; 7(4):543-54. PubMed ID: 17373905
[TBL] [Abstract][Full Text] [Related]
15. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
Jäger E; Karbach J; Gnjatic S; Neumann A; Bender A; Valmori D; Ayyoub M; Ritter E; Ritter G; Jäger D; Panicali D; Hoffman E; Pan L; Oettgen H; Old LJ; Knuth A
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14453-8. PubMed ID: 16984998
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
17. Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules.
Kaufman HL
Ann N Y Acad Sci; 2005 Dec; 1062():41-50. PubMed ID: 16461787
[TBL] [Abstract][Full Text] [Related]
18. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Schlom J; Palena C; Greiner JW; Tsang KY; Grosenbach DW; Sabzevari H; Gulley JL; Arlen PM; Kass E; Hodge JW
Dev Biol (Basel); 2004; 116():27-47. PubMed ID: 15603182
[No Abstract] [Full Text] [Related]
20. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Arlen PM; Gulley JL; Madan RA; Hodge JW; Schlom J
Crit Rev Immunol; 2007; 27(5):451-62. PubMed ID: 18197807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]